Supreme Court Calls For Solicitor’s Views In Biologic Patent Case

(June 20, 2016, 1:23 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court on June 20 invited the government to weigh in on a Federal Circuit U.S. Court of Appeals’ ruling that biosimilar makers must wait until their products receive U.S. Food and Drug Administration approval before providing 180-day advance notice of sales (Sandoz, Inc. v. Amgen, Inc. and Amgen Manufacturing, Ltd., No. 15-1039, U.S. Sup.; Amgen Inc. et al. v. Sandoz Inc., No. 15-1195, U.S. Sup.).

Amgen Inc. and Amgen Manufacturing Ltd. (Amgen, collectively) make the biologic product filgrastim under the...
To view the full article, register now.